Sugi Predict

Sugi Predict / Compounds / SCHEMBL17669241

SCHEMBL17669241

SCHEMBL17669241

CC(C)c1ccc(C(=O)CC2(O)C(=O)Nc3c(Cl)ccc(Cl)c32)cc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FLI1 Q01543 5/20 0.72
▸ EWSR1 Q01844 5/20 0.72
▸ ERG P11308 1/20 0.72
▸ ETV1 P50549 1/20 0.72
▸ ALDH1A1 P00352 3/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ MEN1 O00255 1/20 0.63
▸ HTT P42858 1/20 0.63
▸ NPSR1 Q6W5P4 1/20 0.63
▸ MMP8 P22894 8/20 0.47
▸ MMP9 P14780 7/20 0.47
▸ MMP2 P08253 7/20 0.47
▸ TP53 P04637 3/20 0.46
▸ MAPT P10636 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ USP5 P45974 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17679834 1.00 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL29810795 1.00 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679830 1.00 FLI1 (0.72) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL13253331 0.88 FLI1 (0.73) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL13253318 0.88 FLI1 (0.77) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL13253333 0.87 FLI1 (0.75) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL3486433 0.87 FLI1 (0.75) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679857 0.87 FLI1 (0.75) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL17679858 0.87 FLI1 (0.75) FLI1EWSR1ERGETV1ALDH1A1
SCHEMBL13253323 0.86 ALDH1A1 (0.84) FLI1EWSR1ERGETV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204376-B1 INDOLINONE COMPOUNDS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2023-04-19 — — EP disclosed
EP-3204376-B1 INDOLINONE COMPOUNDS AND USES THEREOF ONCTERNAL THERAPEUTICS INC (US) 2023-04-19 — — EP disclosed
US-20220288023-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2022-09-15 — — US disclosed
CN-111777596-A Indolone compounds and use thereof 英克特诺治疗公司 2020-10-16 — — CN disclosed
US-20200253927-A1 USES OF INDOLINONE COMPOUNDS GEORGETOWN UNIVERSITY 2020-08-13 — — US disclosed
CN-107108580-B Indolone compounds and use thereof 英克特诺治疗公司 2020-06-30 — — CN disclosed
US-10646470-B2 Uses of indolinone compounds Oncternal Therapeutics, Inc. (US) 2020-05-12 — — US disclosed
US-20190022062-A1 USES OF INDOLINONE COMPOUNDS GEORGETOWN UNIVERSITY 2019-01-24 — — US disclosed
US-20180256546-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2018-09-13 — — US disclosed
US-9987251-B2 Indolinone compounds and uses thereof Oncternal Therapeutics, Inc. (US) 2018-06-05 — — US disclosed
US-20170065559-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-03-09 — — US disclosed
US-20170065559-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-03-09 — — US disclosed
US-20170065559-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-03-09 — — US disclosed
US-20170066720-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-03-09 — — US disclosed
US-20170066720-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-03-09 — — US disclosed
WO-2016057698-A1 INDOLINONE COMPOUNDS AND USES THEREOF Tokalas, Inc. (US) 2016-04-14 — — WO disclosed
WO-2016057698-A1 INDOLINONE COMPOUNDS AND USES THEREOF Tokalas, Inc. (US) 2016-04-14 — — WO disclosed
US-20160102055-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2016-04-14 — — US disclosed
US-20160102055-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2016-04-14 — — US disclosed
US-20160102055-A1 INDOLINONE COMPOUNDS AND USES THEREOF GEORGETOWN UNIVERSITY 2016-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200253927-A1 USES OF INDOLINONE COMPOUNDS MCL1, BCL3, BCL9 FLI1 8/4885EWSR1 823/4885ERG 311/4885
US-20170066720-A1 INDOLINONE COMPOUNDS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 4/4885
US-20160102055-A1 INDOLINONE COMPOUNDS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 4/4885
US-10646470-B2 Uses of indolinone compounds MCL1, BCL3, BCL9 FLI1 8/4885EWSR1 823/4885ERG 311/4885
US-20220288023-A1 INDOLINONE COMPOUNDS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 4/4885
US-20170065559-A1 INDOLINONE COMPOUNDS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 4/4885
US-20180256546-A1 INDOLINONE COMPOUNDS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 4/4885
US-20190022062-A1 USES OF INDOLINONE COMPOUNDS MCL1, BCL3, BCL9 FLI1 8/4885EWSR1 823/4885ERG 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.